Analysis on the Efficacy and Safety of the Patients with Advanced Ovarian Cancer

摘要

Objective: To observe and explore the new adjuvant chemotherapy in patients with advanced ovarian cancer with tumour status, surgical effect and prognosis, the influence of provide a reference for clinical rational design of advanced ovarian cancer treatments. Methods: We select 32 cases in treatment group from January 2013 to December 2014, the advanced ovarian cancer treated with neoadjuvant chemotherapy. We select 32 cases of the first line of tumour to destroy loss during this period, all patients with postoperative chemotherapy, observation and comparison, the operation difficulty, tumour residual tumour foci, the differences between the recent prognosis, etc. Results: The III phase c and IV ovarian cancer neoadjuvant chemotherapy group of patients clinical effectiveness were 86.67% and 82.35% respectively; Neoadjuvant chemotherapy group patients had no chemotherapy group of patients with tumour size, water, abdominal operation difficulty, deputy damage and residual tumour foci were significantly reduced; Neoadjuvant chemotherapy group 1 year, 3 year survival rate and survival rate of patients with a median survival time were slightly higher than that of without chemotherapy group, but the differences were not statistically significant. Conclusion: The neoadjuvant chemotherapy can significantly reduce the tumour volume, reduce ascites and metastases, conducive to the operation safety and thoroughness, in spite of the recent advance and been not seen behind the obvious improvement, but still in patients with advanced ovarian cancer is one of the important treatment strategies.